Screening for cytochrome P450 3A in man: Studies with midazolam and nifedipine

Journal of Pharmacy and Pharmacology

Volumn 48, Issue 9, 1996, Pages 933-934

  Yeates, R A ^a   Scharpf, F ^a   Laufen, H ^a   Zimmermann, T ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 ISOENZYME; DRUG METABOLITE; MIDAZOLAM; MIDAZOLAM MALEATE; NIFEDIPINE;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG OXIDATION; ENZYME ACTIVITY; ENZYME SUBSTRATE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PREDICTION; SCREENING TEST;

EID: 0029856875     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.1996.tb06005.x     Document Type: Article

References (19)

1. Allonen, H., Ziegler, G., Klotz, U. (1981) Midazolam kinetics. Clin. Pharmacol. Ther. 30: 653-661
2. Guengerich, F. P., Martin, M. V., Beaune, P. H., Kremers, P., Wolff, T., Waxman, D. J. (1986) Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem. 261: 5051-5060
3. Hunt, C. M., Watkins, P. B., Saenger, P., Stave, G. M., Barlascini, N., Watlington, C. O., Wrighl, J. T., Guzelian, P. S. (1992) Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol. Clin. Pharmacol. Ther. 51: 18-23
4. Kinirons, M. T., O'Shea, D., Downing, T. E., Fitzwilliam, A. T., Joellenbeck, L., Groopman, J. D., Wilkinson, G. R., Wood, A. J. J. (1993) Absence of correlations among three putative in-vivo probes of human cytochrome P450 3A activity in young healthy men. Clin. Pharmacol. Ther 54: 621-629
5. Krivoruk, Y., Kinirons, M. T., Wood, A. J. J., Wood, M. (1994) Metabolism of cytochrome P450 3A substrates in vivo administered by the same route: lack of correlation between alfentanil clearance and erythromycin breath test. Clin. Pharmacol. Ther. 56: 608-614
6. Lown, K. S., Kolars, J. C., Thummel, K. E., Barnett, J. L., Kunze, K. L., Wrighton, S. A., Watkins, P. B. (1994) Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab. Dispos. 22: 947-955
7. Renwick, A. G., Ahsan, C. H., Challenor, V. F., Daniels, R., Macklin, B. S., Waller, D. G., George, C. F. (1992) The influence of posture on the pharmacokinetics of orally administered nifedipine. Br. J. Clin. Pharmacol. 34: 332-336
8. Sachs, L. (1992) Angewandte Statistik, 7th edn, Springer, Berlin, p 540
9. Schellens, J. H. M., Soons, P. A., Breiner, D. D. (1988) Lack of bimodality in nifedipine kinetics in a large population of healthy subjects. Biochem. Pharmacol. 37: 2507-2510
10. Schmid, B. J., Perry, H. E., Idle, J. R. (1988) Determination of nifedipine and its three principal metabolites in plasma and urine by automated electron-capture capillary gas chromatography. J. Chromatogr. 425: 107-119
11. Thummel, D. E., Shen, D. D., Podoll, T. D., Kunze, K. L., Trager, W. F., Hartwell, P. S., Raisys, V. A., Marsh, C. L., McVicar, J. P., Barr, D. M., Perkins, J. D., Carithers, R. L. (1994a) Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J. Pharmacol. Exp. Ther. 271: 549-556
12. Thummel, K. E., Shen, D. D., Podoll, T. D., Kunze, K. L., Trager, W. F., Bacchi, C. E., Marsh, C. L., McVicar, J. P., Barr, D. M., Perkins, J. B., Carithers, R. L. (1994b) Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J. Pharmacol. Ther. 271: 557-566
13. Turgeon, D. K., Leichtman, A. B., Lown, K. S., Normolle, D. P., Deeb, G. M., Merion, R. M., Watkins, P. B. (1994a) P450 3A activity and cyclosporin dosing in kidney and heart transplant recipients. Clin. Pharmacol. Ther. 56: 253-260
14. Turgeon, D. K., Leichtman, A. B., Blake, D. S., Schmouder, R. L., Lown, K. S., Annesley, T. M., Watkins, P. B. (1994b) Prediction of interpatient and intrapatient variation in OG 37-325 dosing requirements by the erythromycin breath test: a prospective study in renal transplant recipients. Transplantation 57: 1736-1741
15. Varhe, A., Olkkola, K. T., Neuvonen, P. J. (1994) Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin. Pharmacol. Ther. 56: 601-607
16. Watkins, P. B. (1994) Noninvasive tests of CYP3A enzymes. Pharmacogenetics 4: 171-184
17. Watkins, P. B., Hamilton, T. A., Annesley, T. M., Ellis, C. N., Kolars, J. C., Voorhees, J. J. (1990) The erythromycin breath test as a predictor of cyclosporin blood levels. Clin. Pharmacol. Ther. 48: 120-129
18. Watkins, P. B., Turgeon, D. K., Saenger, P., Lown, K. S., Kolars, J. C., Hamilton, T., Fishman, K., Guzelian, P. S., Voorhees, J. J. (1992) Comparison of urinary 6-β-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity. Clin. Pharmacol. Ther. 52: 265-273
19. Wrighton, S. A., Stevens, J. C. (1992) The human hepatic cytochromes P450 involved in drug metabolism. Crit. Rev. in Toxicol. 22: 1-21